At the front end of most drug discovery programs lies a step called Target Identification, and a few months ago I sat down with a colleague to discuss their approach to target identification. In particular, “how do you characterize a target”? I was surprised at how much that process can vary from company to company. As […]
Drug Target Identification: And then a miracle occurs Read More »
This weekend’s Network of BioThings hackathon (#hackNoB) was a great success with some really innovative projects making great strides in a short amount of time. The event was hosted by the Jeff Grethe of the Neuroscience Information Framework group at UCSD, and organized by Ben Good (Su Lab @ TSRI), Dexter Pratt (NDEx project) with
Network of BioThings Hackathon #2 Read More »
Recently, Andrew Su of Scripps posted a series of blog entries on the Network of Biothings (NoB) efforts, especially their efforts to uncover use cases that could aid medical research. In a nutshell,”The Network of BioThings aims to structure the biological knowledge found in biomedical research articles by comprehensively annotating BioThings (genes, proteins, mutations, diseases,
Network of BioThings: Making PDFs Useful Read More »
One of the key challenges for bioinformaticians in this age is extracting meaningful findings from abstracts and full text articles. Text mining solutions can only take it so far, and previous comparative studies have shown that Amazon Mechanical Turk solutions and automated text mining solutions have similar levels of success when it comes to identifying terms
Tinkering With Semantic Markup Read More »
Over the past few years, pharmaceutical companies have come to increasingly rely external research to help fill their pipelines. This greater reliance on academic research is not without it’s risks — chief amongst these is the lack of reproducibility. Amgen discovered that 47/53 landmark oncology papers had results that could not be reproduced, and Bayer
Assessing Credibility in Scientific Research Read More »
A recent announcement at the AACRs-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19–23, points to some promising results in recent trials that targeted multiple pathways downstream of KRAS (including PI3K/AKT, RAF/MEK/ERK and RAL). The studies conducted by Barry Nelkin at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins involved pre-clinical
Promising Preclinical Results in Pancreatic Cancer Read More »
I’m a voracious reader of mysteries in my spare time. And some juncture in every story, as the detective finds himself staring at the corpse, they ask the inevitable question “Cui Bono — who benefits?” Oddly enough, this is a question that doesn’t get asked often or early enough in the drug discovery and development
Cui Bono? Finding Super Responders In Clinical Trials Read More »
News In this weeks news: “Pancreas In A Dish” Will Show How Pancreatic Cancer Forms A tiny, living 3-D organ model of pancreatic ducts has been created by researchers in Toronto to help them understand pancreatic cancer, which is one of the deadliest yet least understood of all cancers. This new model could lead to
Pancreatic Cancer News & Articles Read More »
News In this weeks news: AACR: New Treatments Studied for Pancreatic Cancer –Doctors Lounge Targeting the hedgehog signaling pathway with a smoothened antagonist, GDC-0449, in combination with gemcitabine achieves partial response in some metastatic pancreatic cancer patients; and targeted depletion of the multi-functional cell membrane protein RLIP76 can cause pancreatic cancer tumors in mice to
Pancreatic Cancer News and Journal Articles Read More »
This week’s collection of news and journal articles include a number of announcements made at the recent AACR meeting in Chicago. News In this weeks news: Whole genome sequencing not informative for all, Johns Hopkins study shows | e! Science News With sharp declines in the cost of whole genome sequencing, the day of accurately
Pancreatic Cancer News From AACR Read More »
